SWA
PCRX icon

Sutton Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

Sutton Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-162
Closed -$6.25K – 1348
2022
Q4 		$6.25K Sell
162
-517
-76% -$25.2K ﹤0.01% 1066
2022
Q3 		$36.1K Sell
679
-2
-0.3% -$111 0.01% 465
2022
Q2 		$39.7K Sell
681
-132
-16% -$8.65K 0.02% 443
2022
Q1 		$62K Buy
813
+132
+19% +$8.8K 0.02% 348
2021
Q4 		$41K Buy
681
+90
+15% +$4.96K 0.01% 482
2021
Q3 		$33.1K Buy
591
+393
+198% +$22.6K 0.01% 524
2021
Q2 		$12K Sell
198
-391
-66% -$24.8K ﹤0.01% 855
2021
Q1 		$41.3K Buy
589
+391
+197% +$27.9K 0.02% 443
2020
Q4 		$11.8K Sell
198
-226
-53% -$13.2K 0.01% 766
2020
Q3 		$25.5K Buy
424
+295
+229% +$17.1K 0.01% 477
2020
Q2 		$6.77K Sell
129
-2
-2% -$84 ﹤0.01% 800
2020
Q1 		$4.39K Sell
131
-341
-72% -$14.2K ﹤0.01% 856
2019
Q4 		$21.4K Buy
+472
New +$20K 0.01% 580

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Sutton Wealth Advisors's PCRX Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 162 shares — an estimated $6.25K sold.

Sutton Wealth Advisors first reported a position in PCRX in Q4 2019 and held it in 13 quarters. The position peaked at $62K in Q1 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Sutton Wealth Advisors reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • Sutton Wealth Advisors sold 162 Pacira BioSciences shares in Q1 2023, an estimated $6.25K.
  • Sutton Wealth Advisors first reported a position in Pacira BioSciences in Q4 2019 and held it in 13 quarters.
  • Sutton Wealth Advisors's Pacira BioSciences position peaked at $62K in Q1 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.